Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 222

Results For "ET"

10719 News Found

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
Biotech | August 11, 2021

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China

The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial


Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22
News | August 11, 2021

Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22

The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine


Lupin posts net profit of Rs 542.46 cr. in Q1FY22
News | August 11, 2021

Lupin posts net profit of Rs 542.46 cr. in Q1FY22

The profits were bolstered by the Boehringer Ingelheim MEK program income


Sequent Scientific net profit at Rs 87.30 lakh in Q1FY22
News | August 11, 2021

Sequent Scientific net profit at Rs 87.30 lakh in Q1FY22

Formulation business grew by 15 per cent in the quarter


Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
Biotech | August 10, 2021

Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings

A veteran in cell therapy and oncology commercialisation


Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Digitisation | August 10, 2021

Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests

Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection


ALS drug RADICAVA holds promise as it completes four years in US
News | August 10, 2021

ALS drug RADICAVA holds promise as it completes four years in US

Nearly 6,000 patients have been treated with the drug since 2017


Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal Dx Lung and Colon Cancer Assay
Drug Approval | August 10, 2021

Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal Dx Lung and Colon Cancer Assay

The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients


FDA approves Nexviazyme for late-onset Pompe disease
Drug Approval | August 09, 2021

FDA approves Nexviazyme for late-onset Pompe disease

Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells


Antengene and MindRank AI to advance the development of difficult-to-drug molecular targets
Drug Approval | August 09, 2021

Antengene and MindRank AI to advance the development of difficult-to-drug molecular targets

Both companies aim to improve the efficiency and success rate of the current drug discovery process.